PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
September 10, 2025Open Access

Supplementary Figure S3 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047

View Full Paper
Ask AI
Bookmark
Share

Authors

ELEvan J. LipsonSDSonia DolfiHTHao Tang

Discussion

Loading...

Member takes

Overview

Analysis reveals PFS variations according to LAG-3 stratification in melanoma patients receiving relatlimab therapy.

Key Points

  • PFS was notably different between patients with low and medium LAG-3 tumors, indicating potential treatment variability.
  • Patients treated with NIVO plus RELA showed differing outcomes based on LAG-3/CD8+ tumor levels, suggesting biomarker utility.
  • Stratified analyses revealed insights into the different responses to immunotherapy in advanced melanoma patients, shaping future treatment routes.
  • Findings may support the incorporation of LAG-3 as a biomarker for patient stratification in advanced melanoma treatments.

Cite This Study

Lipson et al. (2025) studied this question.

synapsesocial.com/papers/68c182609b7b07f3a060f551https://doi.org/10.1158/1078-0432.30029461
View Full Paper
Ask AI
Bookmark
Share